Match Document Document Title
5763404 Methods for using LHRH antagonists with low histamine release  
Antide is the decapeptide, N-Ac-D-2-Nal,D-pClPhe, D-3-Pal, Ser,NicLys, D-NicLys, Leu, ILys, Pro, D-Ala,NH 2 which is an antagonist of luteinizing hormone releasing hormone (LHRH). This...
5763402 Promotion or inhibition of spermatogenesis  
A method of promoting or inhibiting spermatogenesis, said method comprising administering to a male an effective amount of PACAP, a PACAP agonist, a PACAP antagonist, PC4, a PC4 agonist, or a PC4...
5759991 Neurotrophic peptide derivatives  
The invention provides human- or rat-derived neurotrophic peptides and derivatives thereof, precursor peptides thereof, genes encoding the same, transformants containing recombinant expression...
5760000 Inhibition of liver cancer by the use of GnRH and GnRH analogs  
The invention provides a method for treating liver cancer in a mammal comprising administering to the mammal an inhibitory effective amount of at least one GnRH-related compound. Pharmaceutical...
5753226 Methods of enhancing epithelial cell proliferation  
Methods of enhancing epithelial cell proliferation are disclosed. The methods comprise the step of contacting epithelial cells with a compound that binds to reovirus type 3 receptor. Methods of...
5753617 Peptide inhibitors of cellular adhesion  
Novel cyclic peptides of the selectin 54-63 sequence exhibit unexpected and desired properties. Specific points of cyclization or conformational restriction in conjunction with specific...
5753628 Peptide inhibitors of TNF containing predominantly D-amino acids  
Peptides which consist of six to eight, predominately D-amino acids and which bind to tumor necrosis factor-alpha, prevent tumor necrosis factor-alpha from binding to its receptors and inhibit...
5753621 Pulmonary surfactant protein fragments  
This invention discloses that certain fragments of a pulmonary surfactant protein exhibit unexpected surface activity. These protein fragments are useful in preparing formulations for the treatment...
5753625 Treatment for inhibiting the progression of autoimmune disease  
The progression of autoimmune disease is inhibited by the administration of peptides having the sequence of MHC Class I antigen α1-domains. These fragments include the amino acids between...
5750506 Bradykinin antagonists with extended hydrophobic side chains  
Bradykinin antagonists, particularly Cys 6 analogs, which have an extended hydrophobic side chain.
5747447 Stable polypeptide composition  
A (injectable biologically active) polypeptide is stabilized by dissolving said polypeptide forming a liquid solution in citrate buffer of about pH 5.0-5.5.
5747457 Linear adhesion inhibitors  
Linear peptides of the formula I X-A-Cys(R 1 )-B-Z I, in which A, B, R 1 , X and Z are as defined, are highly active inhibitors of the binding of the...
5744354 Calcineurin inhibitory compounds and anchoring protein to induce IL-2 gene expression  
The present invention provides compositions and methods useful for isolating calcineurin as well as inhibiting calcineurin activity. The compositions are peptides that contain regions that are...
5744450 GnRH analogs  
Peptides which include unnatural amino acids and which either promote or inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads....
5739109 Method of treating neuroinflammatory degenerative diseases  
The present invention relates to a method of treating neuroinflammatory degenerative diseases which are cytokine mediated. The method involves administration of an effective amount of Peptide T or...
5736507 Peptides derived from autoantigen for use in immunotherapy of autoimmue diseases  
The present invention relates to novel peptides derived from the autoantigen HC gp-39, said peptides comprising at least one of the amino acid sequences FGRSFTLAS (SEQ ID No. 1), FTLASSETG (SEQ ID...
5736517 Treatment of cancer with peptides  
A method of treating cancer in a human patient, the method involving administering to the patient a cancer cell inhibiting amount of an analog of a naturally occurring biologically active peptide...
5733880 Anthracene derivatives for use as anticancer agents  
A compound having the structural formula, ##STR1## where R 1 and R 2 are independently hydrogen or hydroxyl. R 2 and R 3 are independently oxo or hydrogen, one of R 5 and R 6 is A--B and the...
5731289 Double-chain hemoregulatory peptides  
The present invention relates to peptide compounds comprising two single-chain hemoregulatory, for example haemopoiesis-inhibiting, peptides linked by a bridging group terminally attached to the...
5728677 Methods of inhibiting T-cell dependent proliferation of peripheral blood lymphocytes using the CD2-binding domain of lymphocyte function associated antigen 3  
Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those...
5719123 Ciclosporin form for pulmonary administration  
Pulmonary administration of Ciclosporin in orthorhombic crystal form (designated "CY-A/X-III"), e.g. for the treatment of obstructive or inflammatory airways disease, e.g. asthma, as well as...
5716935 Use of antiotensin II analogs in tissue repair  
Analogs of angiotensin II are useful in accelerating wound healing. These analogs form the basis of compositions useful for accelerating wound healing, in which the active agent is present in an...
5714469 Method of treating sepsis  
The invention relates to the method of preventing and treating sepsis using (S)-5-oxo-L-prolyl-L-α-glutamyl-L-α-aspartyl-N 8 -(5-amino-1-carboxypentyl)-8-oxo-N 7 - N-...
5712251 Treatment method  
A method of treating prostate cancer in warm-blooded animals comprising administering to warm-blooded animals an effective amount of a peptide of Formula I and an anti-androgen.
5710123 Peptide inhibitors of selectin binding  
The present invention provides novel peptides having as their core region portions of the 109-118 amino acid sequence of P-selectin, E-selectin or L-selectin. The invention also provides...
5710126 T cell epitopes of ryegrass pollen allergen  
The present invention provides isolated peptides of Lol p V, a major protein allergen of the species Lolium perenne. Therapeutic peptides within the scope of the invention comprise at least one T...
5707964 Method for treating cancer  
Certain toxic compounds (T) such as, for example, compounds based upon diphtheria toxin, ricin toxin, pseudomonas exotoxin, α-amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting...
5700779 Bradykinin antagonist peptides incorporating N-substituted glycines  
The present invention provides bradykinin type peptides containing N-substituted glycines, particularly bradykinin antagonist peptides useful for the treatment of conditions mediated by bradykinin...
5698522 6-position modified decapeptide LHRH antagonists  
The present invention provides a class of decapeptide compounds which are potent antagonists of LHRH activity and which have the structure A 1 -D 2 -E 3 -G 4 -J 5 -L 6 -M 7 -Q 8 -R 9 -T 10...
5696087 Method and compositions for reducing cholesterol absorption  
Compositions including all or a portion and chemically or recombinantly synthesized analogues of the carboxy terminal region of bile salt-activated lipase (BAL) are described, which, when orally...
5691307 O.sup.6 -substituted guanine compositions and methods for depleting O.sup.6  
Novel O 6 -substituted guanine compounds and pharmaceutical compositions thereof are useful for effectively reducing O 6 -alkylguanine-DNA alkyltransferase (AGT). The novel compounds are useful...
5688770 Antiglaucoma compositions and methods  
The present invention relates to ophthalmo-logical pharmaceutical compositions comprising a renin inhibitor and to methods for using said composition in the treatment of glaucoma.
5688760 Polypeptides having bone resorption inhibitory activity comprising PTHrP-derived sequences  
Polypeptides comprising an N-terminal amino acid sequence corresponding to amino acids 107-111 of parathyroid hormone related protein (PTHrP) having bone resorption inhibitory activity are...
5686417 Peptide T and related peptides in the treatment of HTLV-1 myelopathy and multiple sclerosis  
A composition useful in treating Multiple Sclerosis and HTLV-1 myelopathy in humans comprises: i) a peptide having as its active portion, an amino acid sequence of the formula: ...
5686416 Increasing blood-brain barrier permeability with permeabilizer peptides  
Peptides called receptor mediated permeabilizers (RMP) increase the permeability of the blood-brain barrier to molecules such as therapeutic agents or diagnostic agents. The permeabilizer A-7 or...
5683982 Synthetic lung surfactant having antioxidant properties  
Synthetic pulmonary surfactants having antioxidant properties consisting of a complex of a polypeptide, with an antioxidant moiety, having an alpha-helical structure and a lipid consisting of one...
5679641 Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes  
A peptide comprising an amino acid sequence derived from human p53 protein, wherein said amino acid sequence has the ability to bind to a human MHC Class I molecule. Its use in prophylactic or...
5679640 Immunosuppressant peptides  
Peptide compositions are provided which bind MHC molecules of interest and inhibit T cell activation. The peptide compositions of the present invention comprise various isosteres of naturally...
5679639 Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation  
The present invention describes polypeptides and anti-peptide antibodies capable of inhibiting serine protease enzymatic activity. In particular, polypeptides and anti-peptide antibodies derived...
5677276 Immobilization of peptides to hyaluronate  
The present invention provides novel conjugates of a synthetic polypeptide containing RGD or (dR)GD and a biodegradable polymer, hyaluronate. The conjugates are prepared by any one of three...
5674848 Bioreactor compositions with enhanced cell binding  
Compositions of the invention include packing materials having compounds thereon with enhanced cell binding with respect to collagen. These packing materials are useful for in vitro uses such as...
5674849 Anti-viral compositions  
An anti-viral composition includes a synergistic combination of an anti-viral nucleoside analogue, which may inhibit a virus-specific enzyme, such as viral thymidine kinase and reverse...
5670482 Neuropeptide Y antagonists  
The present invention relates to peptides which show improved Neuropeptide Y antagonism to pharmaceutical compositions containing such peptides and their use.
5668109 Peptides for inhibiting pepsin release  
Peptides derived from the C terminal sequence of sorbin, but containing at least one D-amino acid residue, inhibit pepsin release and are therefore likely to be useful in the treatment of ulcers or...
5663145 Products for administering an initial high dose of Cetrorelix and producing a combination package for use when treating diseases  
For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of Cetrorelix acetate and one or more maintenance doses...
5661001 High molecular weight desulphatohirudin  
The invention pertains to the field of thrombin inhibitors and describes the production of modified desulphatohirudins, particularly desulphatohirudins, with the aid of genetic engineering. The...
5658885 Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes  
This invention relates to Novel α-aminoacid and α-aminoboronic acid and corresponding peptide analogs of the following formula: ##STR1##
5656601 Acylated splenopentins, methods for their synthesis and their use  
The invention relates to new compounds of acylated splenopentins of Formula I R 1 -arg-lys-(R 2 )-glu-val-tyr(R 3 )R 4 I wherein R 1 , R 2 , R 3 , R 4 are as defined in the specification,...
5652211 Peptides for neutralizing the toxicity of Lipid A  
The present invention is concerned with a peptide composition which includes a peptide having units of the formula: (a) (A) n wherein A is Lysine or Arginine and n is an integer with a minimum...
5650392 Method and composition for the treatment of septic shock  
The present invention contemplates a composition and method for treating septic shock in a mammal or as a prophylactic treatment prior to a surgical procedure, comprising administering a...